Trastuzumab (Anti-HER2) is a recombinant humanized monoclonal antibody targeting HER2 antigen, which is overexpressed in invasive breast cancers. Trastuzumab has been used for the research of HER2 positive Metastatic Breast and Gastric Cancer.
Trastuzumab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to HER2 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Trastuzumab-SAP eliminates cells expressing human HER2. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: trastuzumab, HER2, breast cancer, metastatic, gastric, immunotoxin, streptavidin, saporin